Polycystic Ovary Syndrome

Women's Health
6
Pipeline Programs
9
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
3 programs
1
tredaptivePhase 42 trials
Gonal-f®N/A1 trial
IVF Antagonist ProtocolN/A1 trial
Active Trials
NCT02607293CompletedEst. Jun 2017
NCT01487486Unknown30Est. Jan 2014
NCT01228019Terminated1,166Est. May 2013
+1 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
3 mg DRSP/20 μg EEPhase 41 trial
Active Trials
NCT01360996Completed64Est. Feb 2015
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ElagolixPhase 21 trial
Active Trials
NCT03951077Completed118Est. Feb 2021
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
1
Gonal-F, FostimonPhase 21 trial
Active Trials
NCT01337531UnknownEst. Dec 2011
Spruce Biosciences
Spruce BiosciencesSOUTH SAN FRANCISCO, CA
1 program
1
TildacerfontPhase 21 trial
Active Trials
NCT05370521Terminated27Est. Aug 2023
Abbott
AbbottABBOTT PARK, IL
1 program
1
MetforminPhase 11 trial
Active Trials
NCT02086526Completed68Est. Nov 2016
Verona Pharma
Verona PharmaUK - London
1 program
Inositol + alpha lipoic acidN/A1 trial
Active Trials
NCT04881851Terminated76Est. Mar 2025
Conception
ConceptionCA - Berkeley
1 program
Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetateN/A1 trial
Active Trials
NCT02744131UnknownEst. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bayer3 mg DRSP/20 μg EE
Merck & Co.tredaptive
Spruce BiosciencesTildacerfont
AbbVieElagolix
Genesis TherapeuticsGonal-F, Fostimon
AbbottMetformin
ConceptionOral contraceptive pill combination of ethyl estradiol and Cyproterone acetate
Merck & Co.Gonal-f®
Verona PharmaInositol + alpha lipoic acid
Merck & Co.IVF Antagonist Protocol
Merck & Co.tredaptive

Clinical Trials (11)

Total enrollment: 1,583 patients across 11 trials

NCT01360996Bayer3 mg DRSP/20 μg EE

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Start: Aug 2011Est. completion: Feb 201564 patients
Phase 4Completed
NCT01118598Merck & Co.tredaptive

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

Start: Jun 2010Est. completion: May 201234 patients
Phase 4Completed
NCT05370521Spruce BiosciencesTildacerfont

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Start: May 2022Est. completion: Aug 202327 patients
Phase 2Terminated
NCT03951077AbbVieElagolix

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Start: Aug 2019Est. completion: Feb 2021118 patients
Phase 2Completed
NCT01337531Genesis TherapeuticsGonal-F, Fostimon

Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)

Start: May 2011Est. completion: Dec 2011
Phase 2Unknown
NCT02086526AbbottMetformin

Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

Start: Mar 2014Est. completion: Nov 201668 patients
Phase 1Completed
NCT02744131ConceptionOral contraceptive pill combination of ethyl estradiol and Cyproterone acetate

OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women

Start: May 2016Est. completion: Dec 2019
N/AUnknown
NCT02607293Merck & Co.Gonal-f®

A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation

Start: Dec 2015Est. completion: Jun 2017
N/ACompleted
NCT04881851Verona PharmaInositol + alpha lipoic acid

Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment

Start: May 2015Est. completion: Mar 202576 patients
N/ATerminated
NCT01487486Merck & Co.IVF Antagonist Protocol

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

Start: Dec 2011Est. completion: Jan 201430 patients
N/AUnknown
NCT01228019Merck & Co.tredaptive

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Start: Dec 2010Est. completion: May 20131,166 patients
N/ATerminated

Related Jobs in Women's Health

Senior Medical Science Liaison

Ferring Pharmaceuticals
Bangkok, Thailand
20h ago

Senior Key Account Manager

Ferring Pharmaceuticals
Bucureşti, Romania
1w ago

Territory Representative - Miami

Caldera Medical
Miami, FL, US
1w ago

Sales Representative Gynecological Health

Medtronic
Malaga, Andalucia, Spain
1w ago

Sales Representative, Women's Health - Charleston, SC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Sales Representative, Women's Health- Charlotte, NC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

Related Indications

Endometriosis(43)Menopause(27)Postmenopause(8)Controlled Ovarian Stimulation(5)Vasomotor Symptoms Associated With Menopause(4)Polycystic Ovarian Syndrome(3)Preeclampsia(3)Uterine Fibroids(3)Uterine Leiomyomata (Fibroids)(3)Ovarian Hyperstimulation Syndrome(3)